ATE448791T1 - Methoden und zusammensetzungen für die behandlung von glomerulonephritis - Google Patents

Methoden und zusammensetzungen für die behandlung von glomerulonephritis

Info

Publication number
ATE448791T1
ATE448791T1 AT95919041T AT95919041T ATE448791T1 AT E448791 T1 ATE448791 T1 AT E448791T1 AT 95919041 T AT95919041 T AT 95919041T AT 95919041 T AT95919041 T AT 95919041T AT E448791 T1 ATE448791 T1 AT E448791T1
Authority
AT
Austria
Prior art keywords
compositions
methods
treating glomerulonephritis
glomerulonephritis
treating
Prior art date
Application number
AT95919041T
Other languages
English (en)
Inventor
Mark J Evans
Louis Matis
Eileen Elliott Mueller
Steven H Nye
Scott Rollins
Russell P Rother
Jeremy P Springhorn
Stephen P Squinto
Thomas C Thomas
Yi Wang
James A Wilkins
Original Assignee
Alexion Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22888581&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE448791(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alexion Pharma Inc filed Critical Alexion Pharma Inc
Application granted granted Critical
Publication of ATE448791T1 publication Critical patent/ATE448791T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Manufacturing Of Magnetic Record Carriers (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Lubricants (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT95919041T 1994-05-02 1995-05-01 Methoden und zusammensetzungen für die behandlung von glomerulonephritis ATE448791T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/236,208 US6074642A (en) 1994-05-02 1994-05-02 Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
PCT/US1995/005688 WO1995029697A1 (en) 1994-05-02 1995-05-01 Methods and compositions for the treatment of glomerulonephritis and other inflammatory diseases

Publications (1)

Publication Number Publication Date
ATE448791T1 true ATE448791T1 (de) 2009-12-15

Family

ID=22888581

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95919041T ATE448791T1 (de) 1994-05-02 1995-05-01 Methoden und zusammensetzungen für die behandlung von glomerulonephritis

Country Status (15)

Country Link
US (2) US6074642A (de)
EP (5) EP2270047A3 (de)
JP (5) JP3734266B2 (de)
KR (2) KR100381128B1 (de)
AT (1) ATE448791T1 (de)
AU (1) AU2474795A (de)
BR (1) BR9507594B8 (de)
CA (2) CA2690298A1 (de)
DE (2) DE69536017D1 (de)
DK (1) DK0758904T3 (de)
ES (1) ES2336051T3 (de)
FR (1) FR10C0016I2 (de)
NL (1) NL300433I2 (de)
PT (1) PT758904E (de)
WO (1) WO1995029697A1 (de)

Families Citing this family (268)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395888B1 (en) * 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
DE69534701T2 (de) * 1994-09-23 2006-10-19 Alexion Pharmaceuticals, Inc., Cheshire Verfahren zur behandlung von entzündlichen gelenkerkrankungen
KR100425965B1 (ko) 1998-02-20 2004-04-06 타녹스 인코퍼레이티드 보체 활성화의 억제물질
US7112327B2 (en) 1998-02-20 2006-09-26 Tanox, Inc. Inhibition of complement activation
US6956107B2 (en) 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
DE19913707A1 (de) * 1999-03-26 2000-10-05 Privates Inst Bioserv Gmbh Immunadsorber zur Sepsistherapie
EP1196562A4 (de) * 1999-06-29 2007-01-10 Autogen Res Pty Ltd NEUE GENE UND DEREN VERWENDUNG IN DER MODULIERUNG VON FETTLEIBIGKEIT, DIABETES UND ENERGIEGLEICHGEWICHTSSTöRUNG
AU6110301A (en) 2000-04-29 2001-11-12 Univ Iowa Res Found Diagnostics and therapeutics for macular degeneration-related disorders
EP1325033B1 (de) * 2000-10-10 2009-11-25 Genentech, Inc. Inhibierung von c5 komplement-aktivierung für die behandlung und vorbeugung von xeno-transplantat oder akute vaskuläre abstossung
US20020094332A1 (en) * 2001-01-18 2002-07-18 Alexion Pharmaceuticals Method of prophylaxis against large myocardial infractions
ES2309167T3 (es) 2001-02-19 2008-12-16 Merck Patent Gmbh Metodo para identificar epitotes de celulas t y metodo para preparar moleculas con inmunogenicidad reducida.
US20030109714A1 (en) * 2001-03-22 2003-06-12 Neil Wishart Transition metal mediated process
JP2004536138A (ja) * 2001-07-26 2004-12-02 アレクシオン ファーマシューティカルズ， インコーポレイテッド 認識機能を改善する方法
EP3372243A1 (de) 2001-08-17 2018-09-12 Genentech, Inc. Komplement-inhibitoren, die an c5 und c5a binden, ohne die bildung von c5b zu hemmen
ATE360441T1 (de) * 2001-08-17 2007-05-15 Tanox Inc Komplement-inhibitoren die an c5 und c5a binden ohne die bildung von c5b zu hemmen
EP1461428B1 (de) 2001-12-03 2012-03-21 Alexion Pharmaceuticals, Inc. Verfahren zur Herstellung von Hybridantikörper
WO2003081206A2 (en) * 2002-03-18 2003-10-02 Alexion Pharmaceuticals, Inc. Stratification of patient populations having or suspected of having rheumatoid arthritis
ITMI20021527A1 (it) * 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
CA2496834C (en) * 2002-09-06 2014-03-18 Alexion Pharmaceuticals, Inc. Method of treatment of asthma using antibodies to complement component c5
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
US9415102B2 (en) 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
US7361339B2 (en) * 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
WO2005072380A2 (en) * 2004-01-28 2005-08-11 Chauhan Anil K Membrane attack complexes associated with circulating immune complexes
US20050169921A1 (en) 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
US20070116710A1 (en) * 2004-02-03 2007-05-24 Leonard Bell Methods of treating hemolytic anemia
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
US20090028850A1 (en) * 2004-05-14 2009-01-29 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
US7973134B2 (en) * 2004-07-07 2011-07-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways
US7935790B2 (en) * 2004-10-04 2011-05-03 Cell Singaling Technology, Inc. Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways
US7807789B2 (en) * 2004-12-21 2010-10-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
US20090099340A1 (en) * 2007-10-12 2009-04-16 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
US20070292421A1 (en) * 2005-07-28 2007-12-20 Feinberg Bruce B Method for treating preeclampsia
EP1934867A2 (de) 2005-08-31 2008-06-25 Cell Signaling Technology, Inc. Reagentien zum nachweis der proteinphosphorylierung in leukämie-signalwegen
US20100151495A9 (en) * 2005-08-31 2010-06-17 Cell Signaling Technolgy, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
CA2624393C (en) 2005-11-04 2016-01-05 Genentech, Inc. Use of complement pathway inhibitors to treat ocular diseases
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
US20070196367A1 (en) * 2006-02-22 2007-08-23 Valentin Dinu Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system
WO2007103134A2 (en) * 2006-03-02 2007-09-13 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
HUE026496T2 (en) * 2006-03-08 2016-06-28 Archemix Llc Complement-binding aptamers and anti-C5 agents for treating eye diseases
AU2007225044C1 (en) 2006-03-15 2018-03-29 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
EP2006381B1 (de) 2006-03-31 2016-02-03 Chugai Seiyaku Kabushiki Kaisha Verfahren zur kontrolle der blut-pharmakokinetik von antikörpern
WO2007127335A2 (en) * 2006-04-27 2007-11-08 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in atm and atr kinase signaling pathways
CA2650718A1 (en) * 2006-05-01 2007-11-15 Alexion Pharmaceuticals, Inc. Methods for the treatment of muscular dystrophy associated with dysferlin-deficiency
CN101563363B (zh) 2006-06-21 2013-01-02 南卡罗来纳医疗大学研究发展基金会 用于治疗疾病的靶向补体因子h
US7939636B2 (en) * 2006-08-11 2011-05-10 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in c-Src signaling pathways
US20090258442A1 (en) * 2006-08-31 2009-10-15 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
EP2913342A1 (de) * 2006-09-05 2015-09-02 Alexion Pharmaceuticals, Inc. Zusammensetzungen zur behandlung von antikörpervermittelten neuropathien
CA3154415A1 (en) 2006-10-10 2008-04-17 Regenesance B.V. Anti-sense oligonucleotide for use in facilitating axonal regeneration
WO2008048689A2 (en) * 2006-10-20 2008-04-24 Alexion Pharmaceuticals, Inc. Methods for the treatment of muscular dystrophy associated with dysferlin-deficiency
MY157948A (en) 2006-11-02 2016-08-30 Genentech Inc Humanized anti-factor d antibodies
US20090081659A1 (en) 2007-03-07 2009-03-26 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
EP2129681A2 (de) * 2007-03-22 2009-12-09 Novartis Ag C5-antigene und deren verwendung
EP1975184A3 (de) 2007-03-26 2008-11-26 Cell Signaling Technology, Inc. Serin- oder Threonin-Phosphorylationsorte
US20080238709A1 (en) * 2007-03-28 2008-10-02 Faramarz Vaziri One-way communication apparatus with dynamic key generation
EP1983003A3 (de) 2007-04-19 2009-03-11 Peter Hornbeck Tyrosinphosphorylationsstellen und spezifische Antikörper
EP1983002A3 (de) 2007-04-19 2009-03-11 Peter Hornbeck Tyrosinphosphorylations-Stellen und spezifische Antikörper
US7977462B2 (en) 2007-04-19 2011-07-12 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
US20090053831A1 (en) 2007-05-01 2009-02-26 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
JP5749009B2 (ja) * 2007-08-13 2015-07-15 バスジーン セラピューティクス，インコーポレイテッドＶａｓｇｅｎｅｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ＥｐｈＢ４に結合するヒト化抗体を利用する癌治療剤
PL2202245T3 (pl) 2007-09-26 2017-02-28 Chugai Seiyaku Kabushiki Kaisha Sposób modyfikowania punktu izoelektrycznego przeciwciała poprzez podstawienie aminokwasu w cdr
DK2203558T3 (en) 2007-10-18 2016-06-27 Cell Signaling Technology Inc TRANSLOCATION AND mutant ROS kinase IN HUMAN NON-small cell lung carcinoma
US20090203043A1 (en) 2007-11-21 2009-08-13 Peter Hornbeck Protein phosphorylation by basophilic serine/threonine kinases in insulin signaling pathways
US20090220991A1 (en) * 2008-02-29 2009-09-03 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
WO2009126306A2 (en) 2008-04-10 2009-10-15 Cell Signaling Technology, Inc. Compositions and methods for detecting egfr mutations in cancer
ES2563483T3 (es) 2008-04-11 2016-03-15 Chugai Seiyaku Kabushiki Kaisha Molécula de unión a antígeno capaz de unirse repetidamente a dos o más moléculas de antígeno
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
ES2692291T3 (es) * 2008-05-01 2018-12-03 Complexa Inc. Ácidos grasos vinil sustituidos
US8148088B2 (en) * 2008-07-18 2012-04-03 Abgent Regulation of autophagy pathway phosphorylation and uses thereof
AR072897A1 (es) * 2008-08-05 2010-09-29 Novartis Ag Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5
AU2014201433B2 (en) * 2008-08-05 2016-05-26 Novartis Ag Compositions and methods for antibodies targeting complement protein C5
SI2379066T1 (sl) 2008-09-16 2014-08-29 Imuneks Farma Ilac Sanayi Ve Ticaret A.S. Uporaba opioidnih antagonistov za pripravo zdravila za zdravljenje degenerativnih bolezni retine
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
CN109045296A (zh) 2008-11-10 2018-12-21 阿雷克森制药公司 用于治疗补体相关障碍的方法和组合物
EP2396342B1 (de) 2009-02-12 2014-09-17 Cell Signaling Technology, Inc. Expression mutanter ros bei menschlichem leberkrebs
PT3912643T (pt) 2009-02-13 2023-01-12 Immunomedics Inc Imunoconjugados com uma ligação intracelular clivável
KR20110122846A (ko) 2009-02-24 2011-11-11 알렉시온 파마슈티칼스, 인코포레이티드 치료용 ｔｐｏ/ｅｐｏ 모방 펩티드를 포함하는 항체
US20100248265A1 (en) * 2009-02-27 2010-09-30 The Salk Institute For Biological Studies Compositions and methods for diagnosis and treatment of cancer
AU2010264520A1 (en) 2009-06-23 2012-01-19 Alexion Pharmaceuticals, Inc. Bispecific antibodies that bind to complement proteins
CA2767105A1 (en) 2009-07-02 2011-01-06 Musc Foundation For Research Development Methods of stimulating liver regeneration
US8287865B2 (en) 2009-09-16 2012-10-16 Immunomedics, Inc. Class I anti-CEA antibodies and uses thereof
EP2482816B8 (de) * 2009-10-01 2016-12-14 Imuneks Farma Ilaç Sanayi Ve Ticaret A.S. Topische naltrexon-zusammensetzungen zur behandlung von hauterkrankungen
US10239937B2 (en) 2009-11-05 2019-03-26 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
IN2012DN03354A (de) 2009-12-02 2015-10-23 Immunomedics Inc
NZ602219A (en) * 2010-03-01 2014-10-31 Alexion Pharma Inc Methods and compositions for treating degos’ disease
TWI667257B (zh) * 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
TR201002473A2 (tr) 2010-03-31 2011-09-21 Mustafa Nevzat �La� Sanay�� A.�. Herpes zoster hastalığının bır opiat reseptör antagonist kullanılarak tedavi yöntemi.
EA201291133A1 (ru) * 2010-04-30 2013-04-30 Алексион Фармасьютикалз, Инк. Антитела, обладающие пониженной иммуногенностью в организме человека
DK2563813T3 (en) 2010-04-30 2015-11-30 Alexion Pharma Inc Anti-c5a antibodies and methods of use of antibodies
EA201291241A1 (ru) 2010-05-14 2013-05-30 Дзе Риджентс Оф Дзе Юниверсити Оф Колорадо, Э Боди Корпорейт Улучшенные нацеливающие на рецептор 2 (cr2) комплемента группы
MX2012014975A (es) 2010-06-22 2013-03-12 Univ Colorado Regents Anticuerpos al fragmento c3d de componente 3 de complemento.
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2012019132A2 (en) 2010-08-06 2012-02-09 Cell Signaling Technology, Inc. Anaplastic lymphoma kinase in kidney cancer
TW201241008A (en) * 2010-10-01 2012-10-16 Alexion Pharma Inc Polypeptides that bind to human complement component C5
CA2821992A1 (en) 2010-10-01 2012-04-05 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US20140234340A1 (en) 2010-11-30 2014-08-21 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
EP2468295A1 (de) 2010-12-21 2012-06-27 Affiris AG Impfstoffe basierend auf Komplementprotein C5a Peptide
SG10201609665PA (en) 2011-02-25 2017-01-27 Chugai Pharmaceutical Co Ltd FcɣRIIb-SPECIFIC Fc ANTIBODY
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9867886B2 (en) 2011-04-15 2018-01-16 Snu R&Db Foundation Complex in which anti-cotinine antibody is bound to conjugate of cotinine and binding substance, and use thereof
AU2012250924B2 (en) 2011-05-02 2017-05-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
EP2723361B1 (de) 2011-06-22 2019-10-30 Apellis Pharmaceuticals, Inc. Verfahren zur behandlung chronischer erkrankungen mit komplementinhibitoren
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
TW201817744A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
ES2911677T3 (es) 2011-10-03 2022-05-20 Modernatx Inc Nucleósidos, nucleótidos y ácidos nucleicos modificados, y sus usos
CA3233142A1 (en) 2011-11-30 2013-06-06 Chugai Seiyaku Kabushiki Kaisha Drug containing carrier into cell for forming immune complex
DE12858350T1 (de) 2011-12-16 2021-10-07 Modernatx, Inc. Modifizierte mrna zusammensetzungen
JP6231493B2 (ja) 2011-12-21 2017-11-15 ノバルティス アーゲー Ｐ因子を標的とする抗体のための組成物および方法
PL2817329T3 (pl) 2012-02-20 2019-07-31 Swedish Orphan Biovitrum Ab (Publ) Polipeptydy wiążące z c5 ludzkiego dopełniacza
EP3501550A1 (de) 2012-04-02 2019-06-26 Moderna Therapeutics, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
IN2014KN02324A (de) 2012-04-06 2015-05-01 Omeros Corp
PL2838998T3 (pl) 2012-04-18 2018-04-30 Cell Signaling Technology, Inc. EGFR i ROS1 w nowotworze
KR20200015952A (ko) 2012-06-18 2020-02-13 오메로스 코포레이션 다양한 질환 및 장애의 치료를 위해 masp-1 및/또는 masp-2 및/또는 masp-3를 억제하는 조성물 및 방법
CN104379169A (zh) 2012-08-14 2015-02-25 Ibc药品公司 用于治疗疾病的t-细胞重定向双特异性抗体
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
AU2013302441B2 (en) 2012-08-17 2018-05-10 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
CA2882272C (en) 2012-08-24 2023-08-29 Chugai Seiyaku Kabushiki Kaisha Fc.gamma.riib-specific fc region variant
TW201418707A (zh) * 2012-09-21 2014-05-16 Alexion Pharma Inc 補體組分ｃ５拮抗劑之篩選分析
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
KR102356017B1 (ko) 2012-12-13 2022-01-27 이뮤노메딕스, 인코오포레이티드 개선된 효능 및 감소된 독성을 위한 항체 및 sn-38의 면역컨쥬게이트의 투약
AU2014213147B2 (en) * 2013-01-31 2019-01-17 lmmunAbs Inc. C5 antibody and method for preventing and treating complement-related diseases
AU2014236309A1 (en) 2013-03-14 2015-10-29 Ren Liu Cancer treatment using antibodies that bing cell surface GRP78
PL2970974T3 (pl) 2013-03-14 2018-01-31 Alnylam Pharmaceuticals Inc Kompozycje komponentu C5 dopełniacza iRNA i sposoby ich zastosowania
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2014160958A1 (en) 2013-03-29 2014-10-02 Alexion Pharmaceuticals, Inc. Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
EP2982689B1 (de) 2013-04-02 2020-08-26 Chugai Seiyaku Kabushiki Kaisha Varianten der fc-region
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
EP3290922A1 (de) 2013-08-07 2018-03-07 Alexion Pharmaceuticals, Inc. Biomarkerproteine für das atypische hämolytische urämische syndrom (ahus)
CR20160132A (es) 2013-08-12 2016-08-25 Genentech Inc Composiciones y método para tratar condiciones asociadas con el complemento
US20160184391A1 (en) * 2013-08-16 2016-06-30 Alexion Pharmaceuticals, Inc. Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant
JP7138411B2 (ja) 2013-08-28 2022-09-16 アフィボディ・アーベー 変異した骨格を有する結合ポリペプチド
NZ718153A (en) 2013-08-28 2022-05-27 Ipc Res Llc Stable polypeptides binding to human complement c5
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (de) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynukleotide zur codierung von low-density-lipoprotein-rezeptor
US20150104445A1 (en) 2013-10-10 2015-04-16 Viropharma Holdings Limited Methods of inhibiting the alternative pathway of complement immune system activation and compositions used therein
AU2014362262B2 (en) 2013-12-12 2021-05-13 Alnylam Pharmaceuticals, Inc. Complement component iRNA compositions and methods of use thereof
WO2015103438A2 (en) 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
US20170073754A1 (en) 2014-02-07 2017-03-16 Novartis Ag Impact of genetic factors on disease progression and response to anti-c5 antibody in geographic atrophy
RU2019119862A (ru) * 2014-02-20 2019-07-15 Аллерган, Инк. Антитела к компоненту комплемента c5
WO2015126548A1 (en) 2014-02-21 2015-08-27 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to trop-2 expressing cells
EP3110445A4 (de) 2014-02-25 2017-09-27 Immunomedics, Inc. Humanisierter rfb4-anti-cd22-antikörper
BR112016019526B1 (pt) 2014-02-25 2023-03-28 Achillion Pharmaceuticals, Inc Composto, e, uso de um composto
KR20220164083A (ko) * 2014-02-26 2022-12-12 알러간, 인코포레이티드 보체 성분 c5 항체
NZ711451A (en) 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
CA2944712A1 (en) 2014-05-01 2015-11-05 Genentech, Inc. Anti-factor d antibody variants and uses thereof
EP3636073B1 (de) 2014-05-05 2023-11-15 Regeneron Pharmaceuticals, Inc. Humanisierte c5- und c3-tiere
PL3628680T3 (pl) 2014-06-12 2022-01-10 Ra Pharmaceuticals, Inc. Modulowanie aktywności dopełniacza
EP3160504B1 (de) 2014-06-24 2020-09-16 Immunomedics, Inc. Antihistontherapie für vaskuläre nekrose bei schwerer glomerulonephritis
WO2016033382A1 (en) * 2014-08-27 2016-03-03 Capnia, Inc. Methods for immune globulin administration
WO2016040589A1 (en) 2014-09-12 2016-03-17 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting complement component c5 and methods of use thereof
WO2016057398A1 (en) 2014-10-07 2016-04-14 Immunomedics, Inc. Neoadjuvant use of antibody-drug conjugates
WO2016061065A1 (en) 2014-10-15 2016-04-21 Alexion Pharmaceuticals, Inc. Methods of shifting an isoelectric profile of a protein product and uses thereof
WO2016061066A1 (en) 2014-10-15 2016-04-21 Alexion Pharmaceuticals, Inc. Methods of replicating a large scale eculizumab production cell culture
US20160108357A1 (en) 2014-10-15 2016-04-21 Alexion Pharmaceuticals, Inc. Methods of culturing a cell
US20160168237A1 (en) 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. Method for treating a complement mediated disorder caused by an infectious agent in a patient
KR20230044338A (ko) 2014-12-19 2023-04-03 추가이 세이야쿠 가부시키가이샤 항-c5 항체 및 그의 사용 방법
US20180016327A1 (en) 2015-01-22 2018-01-18 Chugai Seiyaku Kabushiki Kaisha A Combination of Two or More Anti-C5 Antibodies and Methods of Use
HRP20211824T1 (hr) 2015-01-28 2022-03-04 Ra Pharmaceuticals, Inc. Modulatori aktivnosti komplementa
EP3274468B1 (de) 2015-03-25 2019-02-20 Alexion Pharmaceuticals, Inc. Verfahren zur bestimmung der c3- und c5- konvertase protease-aktivität im alternativen komplement-pfad
US20180074077A1 (en) 2015-03-25 2018-03-15 Alexion Pharmaceuticals, Inc. A method for measuring the protease activity of factor d of the alternative complement pathway
CA2981543A1 (en) 2015-04-22 2016-10-27 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
WO2016178980A1 (en) 2015-05-01 2016-11-10 Alexion Pharmaceuticals, Inc. Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of kindney thansplant
EP3302529A4 (de) 2015-06-03 2019-02-06 The Children's Hospital Medical Center Zusammensetzungen und verfahren zur behandlung von gallengangatresie bei neugeborenen
WO2016200627A1 (en) 2015-06-09 2016-12-15 Children's Hospital Medical Center Dosing algorithm for complement inhibitor
EP3307316A1 (de) 2015-06-12 2018-04-18 Alnylam Pharmaceuticals, Inc. Gegen komplementkomponente c5 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon
ES2953441T3 (es) 2015-06-25 2023-11-13 Immunomedics Inc Combinación de anticuerpos anti-hla-dr o anti-Trop-2 con inhibidores de microtúbulos, inhibidores de parp, inhibidores de la cinasa de bruton o inhibidores de la fosfoinositida 3-cinasa mejora significativamente el resultado terapéutico en el cáncer
WO2016209956A1 (en) * 2015-06-26 2016-12-29 Alexion Pharmaceuticals, Inc. A method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant
EP3316885B1 (de) 2015-07-01 2021-06-23 Immunomedics, Inc. Antikörper-sn-38-immunkonjugate mit einem cl2a-linker
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
AR105808A1 (es) 2015-08-26 2017-11-08 Achillion Pharmaceuticals Inc Compuestos de amida para el tratamiento de trastornos médicos
US10000516B2 (en) 2015-08-26 2018-06-19 Achillion Pharmaceuticals, Inc. Phosphonate compounds for treatment of medical disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
WO2017035408A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
WO2017035361A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Disubstituted compounds for the treatment of medical disorders
WO2017035355A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Ether compounds for treatment of medical disorders
WO2017035351A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of medical disorders
AR105809A1 (es) 2015-08-26 2017-11-08 Achillion Pharmaceuticals Inc Compuestos para el tratamiento de trastornos médicos
WO2017035409A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
US20170073399A1 (en) 2015-09-11 2017-03-16 Alexion Pharmaceuticals, Inc. Recombinant glycosylated eculizumab and eculizumab variants
EP3349773A4 (de) 2015-09-14 2019-05-01 Cincinnati Children's Hospital Medical Center Verfahren und zusammensetzungen zur behandlung der gaucher-krankheit durch modulation des c5a-rezeptors
US11203634B2 (en) 2015-10-07 2021-12-21 Alexion Pharmaceuticals, Inc. Methods of treating age-related macular degeneration in a patient comprising administering an anti-C5a antibody
TW201718014A (zh) 2015-10-12 2017-06-01 諾華公司 C5抑制劑於移植相關微血管病之用途
JP7221691B2 (ja) 2015-10-30 2023-02-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド Ｔ細胞媒介性同種移植片血管障害の増悪を抑制する方法
JP2018534930A (ja) 2015-10-30 2018-11-29 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体及びコンジュゲート
CN108472382A (zh) 2015-10-30 2018-08-31 豪夫迈·罗氏有限公司 抗-因子d抗体变体缀合物及其用途
HRP20230182T1 (hr) 2015-12-16 2023-04-14 Ra Pharmaceuticals, Inc. Modulatori aktivnosti komplementa
BR112018009067A8 (pt) 2015-12-18 2019-02-26 Chugai Pharmaceutical Co Ltd anticorpos anti-c5 e métodos de uso
MX2018014560A (es) 2016-05-27 2019-08-12 Alexion Pharma Inc Metodos para el tratamiento de la miastenia gravis generalizada refractaria.
US20190127453A1 (en) 2016-06-07 2019-05-02 Novartis Ag An anti-c5 antibody dosing regimen
EP3469083A1 (de) 2016-06-10 2019-04-17 Alnylam Pharmaceuticals, Inc. Gegen komplementkomponente c5 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung von paroxysmaler nächtlicher hämoglobinurie (pnh)
CN116751293A (zh) 2016-06-14 2023-09-15 瑞泽恩制药公司 抗c5抗体及其用途
CN115925922A (zh) * 2016-06-17 2023-04-07 中外制药株式会社 抗-c5抗体及使用方法
WO2018005552A1 (en) 2016-06-27 2018-01-04 Achillion Pharmaceuticals, Inc. Quinazoline and indole compounds to treat medical disorders
JOP20170154B1 (ar) 2016-08-01 2023-03-28 Omeros Corp تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة
CA3026050A1 (en) 2016-08-05 2018-02-08 Chugai Seiyaku Kabushiki Kaisha Composition for prophylaxis or treatment of il-8 related diseases
JP7256741B2 (ja) 2016-10-12 2023-04-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 感作レシピエントの腎移植における抗体関連型拒絶反応の予防における抗ｃ５抗体の有効性
US11007254B2 (en) 2016-10-17 2021-05-18 Musc Foundation For Research Development Compositions and methods for treating central nervous system injury
EP3529619B1 (de) 2016-10-19 2021-06-30 Alexion Pharmaceuticals, Inc. Verfahren zur quantifizierung von ungebundenem c5a in einer probe
US11965884B2 (en) 2016-10-19 2024-04-23 Alexion Pharmaceuticals, Inc. Method of quantitating unbound C5 in a sample
WO2018081400A1 (en) 2016-10-27 2018-05-03 Alexion Pharmaceuticals Inc. Assay for c5b-9 deposition in complement-associated disorders
CA3045114A1 (en) 2016-12-07 2018-06-14 Ra Pharmaceuticals, Inc. Modulators of complement activity
SG10201908697XA (en) 2017-01-31 2019-10-30 Chugai Pharmaceutical Co Ltd A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
WO2018160892A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for treatment of medical disorders
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
KR102632860B1 (ko) 2017-03-01 2024-02-02 아칠리온 파르마세우티칼스 인코포레이티드 의학적 장애의 치료를 위한 아릴, 헤테로아릴, 및 헤테로사이클릭 약학적 화합물
AU2018237300A1 (en) 2017-03-23 2019-10-17 The Trustees Of The University Of Pennsylvania Anti-C5a antibodies and uses thereof
US11112411B2 (en) 2017-03-31 2021-09-07 Alexion Pharmaceuticals, Inc. Method for simultaneous quantification of ALXN1210 and eculizumab in human serum or urine
EP3411400B1 (de) 2017-04-03 2021-09-22 InflaRx GmbH Behandlung von entzündlichen erkrankungen mit inhibitoren von c5a-aktivität
US10376595B2 (en) 2017-04-03 2019-08-13 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of C5a activity
EP3612561A1 (de) 2017-04-19 2020-02-26 Alexion Pharmaceuticals, Inc. Wirksamkeit eines anti-c5-antikörpers bei der prävention einer antikörpervermittelten abstossung bei sensibilisierten empfängern eines nierentransplantats
IL269895B2 (en) * 2017-04-21 2024-06-01 Volution Immuno Pharmaceuticals Sa Coversin for the treatment of autoimmune blistering diseases
EP3620531A4 (de) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry Verfahren zur vorhersage und beurteilung der therapeutischen wirkung bei erkrankungen im zusammenhang mit il-6 und neutrophilen
ES2967965T3 (es) 2017-05-22 2024-05-06 Alexion Pharma Inc Dosis y administración de anticuerpos anti-C5 para el tratamiento de enteropatía pierde-proteínas en pacientes
EP3658184B1 (de) 2017-07-27 2023-09-06 Alexion Pharmaceuticals, Inc. Hochkonzentrierte anti-c5-antikörperformulierungen
US20200262897A1 (en) 2017-10-04 2020-08-20 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of patients with membranoproliferative glomerulonephritis
US20200254092A1 (en) 2017-10-26 2020-08-13 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus)
AU2018360697A1 (en) 2017-11-01 2020-05-14 Alnylam Pharmaceuticals, Inc. Complement component C3 iRNA compositions and methods of use thereof
AU2018374469B2 (en) 2017-11-29 2022-06-16 F. Hoffmann-La Roche Ag Target interference suppressed anti-drug antibody assay
US12037389B2 (en) 2017-12-01 2024-07-16 Children's Hospital Medical Center Compositions for interferon blockade and methods of using same
EP3724226A1 (de) 2017-12-13 2020-10-21 Regeneron Pharmaceuticals, Inc. Anti-c5-antikörperkombinationen und verwendungen davon
CA3104295A1 (en) * 2018-06-19 2019-12-26 Atarga, Llc Antibody molecules to complement component 5 and uses thereof
TWI704157B (zh) 2018-08-01 2020-09-11 日商中外製藥股份有限公司 在c5相關疾病之治療或預防中使用的醫藥組成物與治療或預防c5相關疾病的方法
US20230022157A1 (en) 2018-08-20 2023-01-26 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
EP3846803A4 (de) 2018-09-06 2022-08-10 Achillion Pharmaceuticals, Inc. Makrocyclische verbindungen zur behandlung von medizinischen erkrankungen
EP3847174A4 (de) 2018-09-06 2022-06-15 Achillion Pharmaceuticals, Inc. Morphische formen von komplementfaktor-d-inhibitoren
JP2022500427A (ja) 2018-09-17 2022-01-04 国立大学法人京都大学 肝傷害又は肝不全の処置のための抗ｃ５剤の投与
EP3852876A1 (de) 2018-09-21 2021-07-28 Alexion Pharmaceuticals, Inc. Eculuzimab zur behandlung von neuromyelitis opticae
CA3114039A1 (en) 2018-09-25 2020-04-02 Achillion Pharmaceuticals, Inc. Morphic forms of complement factor d inhibitors
WO2020092546A1 (en) 2018-10-30 2020-05-07 Alexion Pharmaceuticals, Inc. Co-administration of a hyaluronidase and anti-c5 antibody for treatment of complement-associated conditions
KR20210084533A (ko) 2018-10-30 2021-07-07 알렉시온 파마슈티칼스, 인코포레이티드 발작성 야간 혈색소뇨증 (pnh)의 치료를 위한 항-c5 항체의 피하 투여량 및 투여
WO2020106724A1 (en) 2018-11-20 2020-05-28 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis in pediatric patients
EP3730617A1 (de) 2019-04-26 2020-10-28 Silence Therapeutics GmbH Nukleinsäure zur hemmung der expression von c3 in einer zelle
CA3119234A1 (en) 2018-11-23 2020-05-28 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of c3 in a cell
GB2583560A (en) 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
CN117838856A (zh) 2019-01-25 2024-04-09 亚力兄制药公司 用于治疗非典型溶血性尿毒综合征(ahus)的抗c5抗体的剂量和施用
US20220227851A1 (en) 2019-05-24 2022-07-21 Alexion Pharmaceuticals, Inc. Methods of treating vitiligo using an anti-c5 antibody
CN114929273A (zh) 2019-07-31 2022-08-19 豪夫迈·罗氏有限公司 通过使用抗c5抗体可伐利单抗来治疗或预防c5相关疾病的剂量和施用方案
EP4003408A1 (de) 2019-07-31 2022-06-01 F. Hoffmann-La Roche AG Dosierungs- und verabreichungsschema zur behandlung oder vorbeugung von c5-bedingten krankheiten durch verwendung des anti-c5-antikörpers crovalimab
US20220259305A1 (en) 2019-08-05 2022-08-18 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis with eculizumab
CN114981430A (zh) 2019-08-27 2022-08-30 赛伦斯治疗有限责任公司 用于抑制细胞中的c3表达的核酸
TW202134435A (zh) 2019-10-22 2021-09-16 美商阿尼拉製藥公司 補體成分ｃ３ ｉｒｎａ組成物及其使用方法
JP2023507852A (ja) 2019-12-23 2023-02-27 アレクシオン ファーマシューティカルズ， インコーポレイテッド 抗ｃ５抗体を使用して妊娠関連非典型溶血性***症候群を治療する方法
WO2021154941A1 (en) 2020-01-31 2021-08-05 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
EP4114947A1 (de) 2020-03-05 2023-01-11 Alnylam Pharmaceuticals, Inc. Komplementkomponenten-c3-irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung oder prävention von mit komplementkomponenten-c3-assoziierten erkrankungen
US20230158060A1 (en) 2020-03-27 2023-05-25 Inflarx Gmbh Inhibitors of C5a for the Treatment of Corona Virus Infection
CN116406287A (zh) 2020-04-16 2023-07-07 巴黎公共医疗救助机构 治疗由病毒引起的补体介导的障碍的方法
MX2022013606A (es) 2020-04-30 2023-01-16 Alnylam Pharmaceuticals Inc Composiciones de ácido ribonucleico interferente (arni) del factor b de complemento (cfb) y métodos de uso de las mismas.
WO2021231470A1 (en) 2020-05-12 2021-11-18 Alexion Pharmaceuticals, Inc. Use of complement factor d inhibitors alone or in combination with anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria
EP4161653A1 (de) 2020-06-03 2023-04-12 Bionecure Therapeutics, Inc. Trophoblastzelloberflächenantigen-2 (trop-2)-antikörper
AU2021294222A1 (en) 2020-06-16 2023-01-19 F. Hoffmann-La Roche Ag Method for determining the free antigen of an antibody in a sample
WO2021262329A1 (en) 2020-06-24 2021-12-30 Alexion Pharmaceuticals, Inc. Subcutaneous (sc) administration of anti-c5 antibodies for treatment of complement-associated conditions
US20230256114A1 (en) 2020-07-07 2023-08-17 Bionecure Therapeutics, Inc. Novel maytansinoids as adc payloads and their use for the treatment of cancer
WO2022012606A1 (en) * 2020-07-15 2022-01-20 Biosion Inc. Antibodies binding c5 and uses thereof
EP4274896A1 (de) 2021-01-05 2023-11-15 Alnylam Pharmaceuticals, Inc. Komplementkomponente 9 (c9)-irna-zusammensetzungen und verfahren zur verwendung davon
WO2022159984A1 (en) 2021-01-22 2022-07-28 Bionecure Therapeutics, Inc. Anti-her-2/trop-2 constructs and uses thereof
EP4378479A2 (de) 2021-01-22 2024-06-05 Alexion Pharmaceuticals, Inc. Verfahren zur behandlung von komplementvermittelter thrombotischer mikroangiopathie unter verwendung eines anti-c5-antikörpers
WO2022239720A1 (ja) 2021-05-10 2022-11-17 公益財団法人川崎市産業振興財団 抗原への結合親和性を低減させた抗体
WO2022251446A1 (en) 2021-05-28 2022-12-01 Alexion Pharmaceuticals, Inc. Methods for detecting cm-tma biomarkers
WO2023023220A1 (en) 2021-08-20 2023-02-23 Alexion Pharmaceuticals, Inc. Methods for treating sickle cell disease or beta thalassemia using a complement alternative pathway inhibitor
EP4396346A1 (de) 2021-09-02 2024-07-10 Silence Therapeutics GmbH Nukleinsäuren zur hemmung der expression des komplementfaktors b (cfb) in einer zelle
EP4402174A1 (de) 2021-09-17 2024-07-24 Novartis AG Verfahren zur prävention von transplantatabstossung bei xenotransplantation
WO2023044370A2 (en) 2021-09-17 2023-03-23 Alnylam Pharmaceuticals, Inc. Irna compositions and methods for silencing complement component 3 (c3)
KR20240095325A (ko) 2021-10-29 2024-06-25 알닐람 파마슈티칼스 인코포레이티드 보체 인자 b (cfb) irna 조성물 및 이의 사용 방법
CN116712390B (zh) * 2023-08-04 2023-11-14 上海览屹医药科技有限公司 一种高浓度高稳定性的抗体制剂及其制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4578335A (en) 1984-05-21 1986-03-25 Immunex Corporation Interleukin 2 receptor
US4845198A (en) 1984-05-21 1989-07-04 Immunex Corporation Hybridoma antibody which binds IL-2 receptor
US4686100A (en) * 1985-04-02 1987-08-11 The Board Of Trustees Of The Leland Stanford Junior University Method for the treatment of adult respiratory distress syndrome
US4816565A (en) 1985-08-13 1989-03-28 Tasuku Honjo Interleukin 2 receptor and a method for production thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5173499A (en) * 1988-04-15 1992-12-22 T Cell Sciences, Inc. Compounds which inhibit complement and/or suppress immune activity
US5506247A (en) * 1988-04-15 1996-04-09 T Cell Sciences, Inc. Compounds that inhibit complement and/or suppress immune activity
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2011450C (en) 1989-03-07 2002-06-04 Tadatsugu Taniguchi Recombinant b-chain of the il-2 receptor
US5135916A (en) * 1989-06-12 1992-08-04 Oklahoma Medical Research Foundation Inhibition of complement mediated inflammatory response
DE3924924A1 (de) 1989-07-27 1991-02-07 Goetze Otto Verfahren zum nachweis und/oder der quantitativen bestimmung von komplementpeptid c5a und/oder c5adesarg
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
EP1132471A3 (de) 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag TNF-bindende Proteine
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
FR2671350A1 (fr) 1991-01-08 1992-07-10 Adir Nouveaux derives de benzisoxazole et de benzisothiazole, leur procede de preparation, et les compositions pharmaceutiques les renfermant.
GB9120467D0 (en) * 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
CA2126182C (en) 1991-12-20 2001-07-17 Man S. Co Humanized antibodies reactive with gpiib/iiia
EP0649468B1 (de) * 1992-06-24 2000-03-15 AdProTech plc Lösliche derivate des complement type-rezeptors (cr1)

Also Published As

Publication number Publication date
JP3734266B2 (ja) 2006-01-11
EP2270046A3 (de) 2011-03-23
EP0758904A4 (de) 2005-04-20
EP0758904A1 (de) 1997-02-26
NL300433I1 (en) 2010-03-01
DK0758904T3 (da) 2010-01-18
EP2112165A2 (de) 2009-10-28
JP2006020633A (ja) 2006-01-26
EP2298808A1 (de) 2011-03-23
EP2270046A2 (de) 2011-01-05
US6074642A (en) 2000-06-13
JP4294596B2 (ja) 2009-07-15
KR100442019B1 (ko) 2004-07-30
EP2112165A3 (de) 2011-03-23
JP5047996B2 (ja) 2012-10-10
ES2336051T3 (es) 2010-04-07
EP0758904B1 (de) 2009-11-18
CA2690298A1 (en) 1995-11-09
DE122009000075I1 (de) 2010-05-12
EP2270047A2 (de) 2011-01-05
DE69536017D1 (de) 2009-12-31
KR100381128B1 (ko) 2003-09-29
PT758904E (pt) 2010-02-10
JPH10500289A (ja) 1998-01-13
JP2005185286A (ja) 2005-07-14
BR9507594A (pt) 1997-09-16
JP2012095650A (ja) 2012-05-24
AU2474795A (en) 1995-11-29
CA2189015C (en) 2010-04-13
KR20040000388A (ko) 2004-01-03
FR10C0016I1 (de) 2010-04-30
WO1995029697A1 (en) 1995-11-09
NL300433I2 (en) 2010-04-01
BR9507594B1 (pt) 2010-08-10
BR9507594B8 (pt) 2015-06-02
CA2189015A1 (en) 1995-11-09
EP2270047A3 (de) 2011-03-23
JP2009165471A (ja) 2009-07-30
FR10C0016I2 (fr) 2011-04-01
US6355245B1 (en) 2002-03-12

Similar Documents

Publication Publication Date Title
ATE448791T1 (de) Methoden und zusammensetzungen für die behandlung von glomerulonephritis
DE69014030D1 (de) Mittel für die Verhütung und Behandlung von Diarrhöe.
ATE209218T1 (de) Antikörper die den erythropoetinrezeptor aktivieren
ATE231724T1 (de) Kombinationstherapie für die behandlung von psychosen
DE69927823D1 (de) Hydrogel für die therapeutische behandlung von aneurysmas
FR12C0004I1 (de)
ATE347565T1 (de) Bispezifischer antikörper zur effektiven behandlung von b-zell lymphomen und zellinien
DE60218493D1 (de) Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
ATE202940T1 (de) Mittel und methoden zur behandlung von plaque- krankheiten
ES2194960T3 (es) N-(2-sustituido-3-(2-aminoetil)-1h-indol-5-il)-amidas como nuevos agonistas de 5-ht1f.
DE69528475D1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
DE69633717D1 (de) Monoklonale anti-cd6 antikörper zur behandlung und diagnose von psoriasis
DE59711148D1 (de) Vorrichtung für die behandlung von körpersubstanzen
DE69525279D1 (de) Behandlung von Leder zum Einfärben desselben, sowie gefärbtes Leder
DE3782214D1 (de) Mittel zur behandlung des scheidenmilieus.
ATE173625T1 (de) Zusammensetzungen zur behandlung von hiv- infektionen
DE69110713D1 (de) 7-Oxabicycloheptan-imidazol-prostaglandin-Analoge, verwendbar bei der Behandlung von thrombotischen und vasospastischen Erkrankungen.
DE69631381T2 (de) Therapeutische und diagnostische agenzien zur behandlung mikrobieller infektionen
DE69615843D1 (de) Il-8 antagonisten zur behandlung von asthma
DE59801385D1 (de) Durchlaufanlage für die behandlung von werkstücken
IT8323509A0 (it) Procedimento per trattare riso con pula unita ad esso e riso greggio, nonche' riso trattato con esso ottenuto.
DE69622889D1 (de) Substituierte 4-(1h-benzimidazol-2-yl)(1,4)diazepane für die behandlung von allergischen krankheiten
DE69736180D1 (de) Behandlung von manischen erkrankungen
DE69625104D1 (de) Verwendung von chemischem Mittel für die Behandlung von Textilien
DE69012883D1 (de) Methode für die Behandlung von Abgas.